Yuanhua Intelligence Completes Hundreds of Millions RMB Series B Financing to Advance Surgical Robot Commercialization and Clinical Development

Yuanhua Robotics, Perception and AI Technologies Limited (“Yuanhua Tech”) has recently completed a Series B financing round amounting to hundreds of millions of RMB. The round was led by Capital Partners, with continued joint lead investment from existing shareholders Shenzhen Capital Group Co., Ltd. (SCGC) and Sequoia China. Other prominent institutional investors, including CAS Star and Wanhui Capital, also participated in the financing.

This round of financing will support the company’s comprehensive commercialization strategy for its orthopedic surgical robots, accelerate the clinical development of its gastrointestinal products and natural orifice surgical robots, and drive the final testing and commercial application of its self-developed collaborative robotic arms.

Yuanhua Tech is an innovative high-tech enterprise specializing in cross-departmental specialized surgical robots.Its wholly-owned subsidiary, Gusheng Yuanhua Robotics (Shenzhen) Co., Ltd., has as its core product a world-leading total orthopedic surgical assistance robot system. This system can assist physicians in performing various orthopedic procedures, including knee and hip arthroplasty, trauma surgery, and spinal surgery. Notably, the robotic system for total knee arthroplasty was developed under the leadership of the National Clinical Research Center for Orthopedics, Sports Medicine, and Rehabilitation.On December 31, 2020, a multicenter randomized controlled clinical trial was jointly completed by the First Medical Center of the Chinese PLA General Hospital, West China Hospital of Sichuan University, the First Affiliated Hospital of Xinjiang Medical University, Xiangya Hospital of Central South University, and the Second Affiliated Hospital of the Army Medical University of the Chinese People's Liberation Army.and entered the “Special Review Procedures for Innovative Medical Devices》, currently in the registration application stage.

In January 2022, clinical enrollment began for the total hip arthroplasty indication of the Gusheng Yuanhua Surgical Assistance Robot. A multicenter randomized controlled trial was jointly conducted by the First Medical Center of the Chinese PLA General Hospital, West China Hospital of Sichuan University, the Fourth Medical Center of the Chinese PLA General Hospital, Guangdong Provincial People's Hospital, the Second Affiliated Hospital of Army Medical University of the Chinese PLA, and Ruijin Hospital affiliated with Shanghai Jiao Tong University.

In terms of product lines, Yuanhua Tech’s gastrointestinal products and natural orifice surgical robot products have completed or are nearing completion of preclinical R&D, and will sequentially enter the clinical validation phase, forming a product matrix that covers multiple departments and diverse clinical applications.In terms of core components, in addition to the first-generation self-developed navigation solution that has already been applied for product registration, the new generation of self-developed navigation equipment and collaborative robotic arms specifically designed for orthopedic surgery have both completed final testing and will be put into application within the year.Yuanhua Tech Becomes the First Company in China with In-House R&D Capabilities for All Core Components of Orthopedic Surgical Robot Systems

Cornerstone Capital is one of China’s earliest private equity investment firms, established in 2001 with over two decades of investment management experience. Headquartered in Shenzhen, the company maintains branch offices in Beijing, Shanghai, Hong Kong, Hefei, and Nanjing. To date, Cornerstone Capital has managed more than 80 investment funds across angel investing, venture capital (VC), private equity (PE), mergers and acquisitions (M&A), private placements, and private securities, with cumulative assets under management nearing RMB 60 billion, placing it among the industry leaders nationwide.

Adhering to the investment philosophy of “focused investing and dedicated service,” Co-Stone Capital has cultivated and nurtured a cohort of industry leaders and niche market champions in sectors such as technology, healthcare, and consumer services, delivering sustained, stable, and superior historical returns.

Shenzhen Capital Group Co., Ltd. is committed to its mission of discovering and empowering great enterprises, striving to be a discoverer and cultivator of innovative value. Since its establishment in 1999, SCGC has managed total assets exceeding RMB 400 billion, invested in more than 1,000 innovative high-tech enterprises, and facilitated the IPOs of 183 portfolio companies. Its investments span across industries such as information technology, internet/new media/cultural creativity, biotechnology/healthcare, new energy/energy conservation and environmental protection, new materials/chemicals, high-end equipment manufacturing, and consumer goods/modern services, covering the full life cycle of enterprises.

Established in 2018, the Shenzhen Capital Group Hongtu Healthcare Industry Fund is the first healthcare-focused fund launched by Shenzhen Capital Group (SCGC) as part of its “specialization” strategy. The fund is dedicated to identifying high-quality investment targets with strong innovation capabilities and significant growth potential, thereby driving industrial development. Within less than three years, the fund has invested in more than ten outstanding companies, including Akeso Inc., YHLO Biotech, Medcaptain, Linknew Medical, Lidakang, Kangsheng Medical, Shanghai Zhimeng, GenFleet Therapeutics, and Yuanhua Tech.

Sequoia China is committed to helping entrepreneurs build enduring, great companies by bringing rich global resources and valuable historical experience to its portfolio companies. As “entrepreneurs behind entrepreneurs,” Sequoia China focuses on investment opportunities in technology, consumer, and healthcare sectors. Over the past 17 years, Sequoia China has invested in more than 900 companies with distinct technological features, innovative business models, high growth potential, and strong development prospects.

Guoke Jiahe (Beijing) Investment Management Co., Ltd. was established in 2011. Initiated by CAS Holdings Co., Ltd. (hereinafter referred to as “CAS Holdings”) as the cornerstone investor and jointly founded with several large domestic enterprise groups, it is an equity investment fund manager. It is also the only full-cycle professional technology investment institution directly affiliated with CAS Holdings that covers angel, venture capital (VC), and private equity (PE) stages. Guoke Jiahe has consistently leveraged the leading role of “technology capital” in hard-tech investments, having invested in over one hundred high-tech innovative projects with technological barriers across the two major sectors of TMT and healthcare.

Qianhai Wanhui Equity Investment Management (Shenzhen) Co., Ltd. (hereinafter referred to as “Wanhui Capital”) is the innovative financial sector established by the K. Wah Group in the Guangdong-Hong Kong-Macao Greater Bay Area. It focuses on identifying investment opportunities in the healthcare sector, particularly in biopharmaceuticals and medical devices, to support the development of China’s life and health industry. To date, the company has invested in well-known biotechnology and medical device enterprises such as Akeso, Duoxi Biologics, MicroPort CRM, and Shangjian Biologics. The K. Wah Group has long been committed to supporting the advancement of life sciences. It has made donations to the schools of life sciences and medical schools at prestigious domestic and international universities, including Peking University, Tsinghua University, Stanford University, and the University of California. Additionally, the Group presents the “Lui Che Woo Prize” to numerous distinguished scientists and organizations that have made significant contributions to life sciences and medicine, such as Médecins Sans Frontières (MSF) and Professor Jennifer A. Doudna, thereby vigorously promoting the global development of life sciences and medicine for the betterment of humanity’s future.